From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: OBD

Search articles by EPIC code

Oxford BioDynamics – interims, funding outlook ‘as was the case at the previous period end’… but what about the already-raised net £8.5m since then?!

Describing itself as “a biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform”, Oxford BioDynamics (OBD) has announced results for its half-year ended 31st March 2023 emphasising “excellent progress across the business. There was sustained growth in orders of EpiSwitch CiRT tests, which has continued post-period end. Overwhelming demand for the PSE blood test after announcement of its high accuracy performance”. So what of a current share price response towards 13p, down approaching 22%?!
Page 1 of 1 (4 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments

Time left: 15:27:19